Literature DB >> 16013025

CD20-positive infiltrates in human membranous glomerulonephritis.

Clemens D Cohen1, Novella Calvaresi, Silvia Armelloni, Holger Schmid, Anna Henger, Undine Ott, Maria P Rastaldi, Matthias Kretzler.   

Abstract

Membranous glomerulonephritis (MGN), histologically defined by subepithelial immune deposits, is the most common cause of nephrotic syndrome in Caucasian adults. The current hypothesis of the underlying disease mechanism postulates production of antibodies against podocyte-derived antigens. Respective antigens could be demonstrated in different animal models and recently in human neonatal MGN. Further support for this hypothesis was generated by the response of human MGN to therapeutic B cell depletion by rituximab. However, the role of B cells in this disease is not well defined. In this study, the interstitial expression of CD20 mRNA was determined in 31 MGN patients and controls (tumor nephrectomies (n = 4), minimal change disease (MCD, n = 10) and focal segmental glomerulosclerosis (n = 6)). CD20 mRNA expression was significantly higher in MGN patients compared to controls. By immunohistochemistry, a focal or diffuse interstitial B cell infiltration could be detected in MGN patients (n = 63), which was absent or minimal in patients with MCD (n = 11). These data suggest an involvement of B cells in the pathogenesis of MGN, possibly as antigen-presenting cells. Further studies should investigate the potential to predict the response to therapeutic B cell depletion by intrarenal CD20 quantification, a potential diagnostic basis for the selection of a specific therapy currently evolving for renal disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16013025

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  26 in total

1.  Successful treatment and clearing of circulating CD19-positive cells by rituximab in a child with idiopathic membranous nephropathy.

Authors:  Bizhen Zhu; Jianping Huang
Journal:  Pediatr Nephrol       Date:  2010-10-29       Impact factor: 3.714

Review 2.  B Cells, Antibodies, and More.

Authors:  William Hoffman; Fadi G Lakkis; Geetha Chalasani
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 8.237

3.  In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.

Authors:  Anthony Chang; Scott G Henderson; Daniel Brandt; Ni Liu; Riteesha Guttikonda; Christine Hsieh; Natasha Kaverina; Tammy O Utset; Shane M Meehan; Richard J Quigg; Eric Meffre; Marcus R Clark
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

4.  The contribution of B cells to renal interstitial inflammation.

Authors:  Florian Heller; Maja T Lindenmeyer; Clemens D Cohen; Ulrike Brandt; Dan Draganovici; Michael Fischereder; Matthias Kretzler; Hans-Joachim Anders; Thomas Sitter; Isabella Mosberger; Dontscho Kerjaschki; Heinz Regele; Detlef Schlöndorff; Stephan Segerer
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

5.  Characterisation of renal immune cell infiltrates in children with nephrotic syndrome.

Authors:  Kerstin Benz; Maike Büttner; Katalin Dittrich; Valentina Campean; Jörg Dötsch; Kerstin Amann
Journal:  Pediatr Nephrol       Date:  2010-04-13       Impact factor: 3.714

Review 6.  Rituximab therapy for membranous nephropathy: a systematic review.

Authors:  Andrew S Bomback; Vimal K Derebail; Julie G McGregor; Abhijit V Kshirsagar; Ronald J Falk; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-11       Impact factor: 8.237

Review 7.  Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal.

Authors:  Paolo Cravedi
Journal:  Nephron       Date:  2016-09-28       Impact factor: 2.847

8.  Cystic renal disease in the domestic ferret.

Authors:  Courtnye N Jackson; Arlin B Rogers; Kirk J Maurer; Jennifer L S Lofgren; James G Fox; Robert P Marini
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

Review 9.  Targeting the B cell in vasculitis.

Authors:  Michael Walsh; David Jayne
Journal:  Pediatr Nephrol       Date:  2008-10-18       Impact factor: 3.714

10.  Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients.

Authors:  Alfons Segarra; Manuel Praga; Natalia Ramos; Natalia Polanco; Isabel Cargol; Elena Gutierrez-Solis; M Rosa Gomez; Bruno Montoro; Joaquim Camps
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-28       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.